CytomX Therapeutics to Announce Full-Year 2016 Financial Results
2017年3月1日 - 10:00PM
CytomX Therapeutics, Inc. (Nasdaq:CTMX), a biopharmaceutical
company developing investigational Probody™ therapeutics for the
treatment of cancer, plans to report full-year 2016 financial
results on March 2, 2017, after the NASDAQ market close.
The company will not conduct a conference call in conjunction
with this financial results press release.
About CytomX TherapeuticsCytomX is a
clinical-stage, oncology-focused biopharmaceutical company
pioneering a novel class of investigational antibody therapeutics
based on its Probody technology platform. The company uses the
platform to create proprietary cancer immunotherapies against
clinically-validated targets, such as PD-L1, and first-in-class
cancer therapeutics against novel targets, such as CD166, that are
difficult to drug without causing damage to healthy tissues.
Probody therapeutics are designed to take advantage of unique
conditions in the tumor microenvironment to enhance the
tumor-targeting features of an antibody and reduce drug activity in
healthy tissues. The company’s lead program, CX-072, a
wholly-owned PD-L1-targeting Probody therapeutic, is being
evaluated in a Phase 1/2 study. The Investigational New Drug filing
for CX-2009 is slated for the first half of 2017. CX-2009 is
a first-in-class Probody drug conjugate targeting the highly
expressed tumor antigen, CD166. Both clinical trials are
modules within PROCLAIM (Probody Clinical Assessment In Man), an
international umbrella clinical trial program that provides
clinical trial sites with access to the company’s novel therapies
under one central protocol. In addition to its proprietary
programs, CytomX is collaborating with strategic partners including
AbbVie, Bristol-Myers Squibb Company, Pfizer Inc., MD Anderson
Cancer Center and ImmunoGen, Inc. For more information, visit
www.cytomx.com or follow us on Twitter.
CytomX Therapeutics Forward-Looking
StatementsThis press release includes forward-looking
statements. Such forward-looking statements involve known and
unknown risks, uncertainties and other important factors that are
difficult to predict, may be beyond our control, and may cause the
actual results, performance or achievements to be materially
different from any future results, performance or achievements
expressed or implied in such statements. Accordingly, you should
not rely on any of these forward-looking statements. Our Probody
platform is beginning clinical development, and the process by
which clinical development could potentially lead to an approved
product is long and subject to significant risks and uncertainties.
Projected net cash utilization and capital resources are subject to
substantial risk of variance based on a wide variety of factors
that can be difficult to predict. Applicable risks and
uncertainties include those relating to our preclinical research
and development, clinical development, and other risks identified
under the heading "Risk Factors" included in our filings with the
SEC. The forward-looking statements contained in this press release
are based on information currently available to CytomX and speak
only as of the date on which they are made. CytomX does not
undertake and specifically disclaims any obligation to update any
forward-looking statements, whether as a result of any new
information, future events, changed circumstances or otherwise.
Corporate Communications Contact:
Canale Communications
Ian Stone
ian@canalecomm.com
619-849-5388
Investor Contact:
Trout Group
Pete Rahmer
prahmer@troutgroup.com
646-378-2973
CytomX Therapeutics (NASDAQ:CTMX)
過去 株価チャート
から 6 2024 まで 7 2024
CytomX Therapeutics (NASDAQ:CTMX)
過去 株価チャート
から 7 2023 まで 7 2024